Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7

De Laurentiis, M.Merino, L. de la CruzHart, L.Bardia, A.Im, S-A.Sohn, J.Neven, P.Martin, M.Ji, Y.Yang, S.Hu, H.Lteif, A.Tripathy, D.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27555enImpact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7conference outputopen access10.1016/j.annonc.2020.08.4331569-8041http://www.annalsofoncology.org/article/S0923753420404296/pdf573469100331